Jürg Nussberger - ARCHIVE

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


452 publications

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | ...
Angiotensinergic Innervation of the Human Right Atrium: Implications for Cardiac Reflexes.
Bohlender J.M., Nussberger J., Tevaearai H., Imboden H., 2018/01/12. American journal of hypertension, 31 (2) pp. 188-196. Peer-reviewed.
 
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Engeli S., May M., Nussberger J., Danser AHJ, Dole W.P., Prescott M.F., Dahlke M., Stitah S., Pal P., Boschmann M. et al., 2017/08. Journal of the American Society of Hypertension, 11 (8) pp. 488-497. Peer-reviewed.
 
Are ACE inhibitors acceptable ingredients in polypills?
Messerli F.H., Bangalore S., Rimoldi S.F., Gąsowski J., Nussberger J., 2017/07/01. Lancet, 390 (10089) p. 26. Peer-reviewed.
 
Prévalence d’une sténose carotidienne chez le nonagénaire : résultats d’une enquête hospitalière [Prevalence of carotid artery stenosis in nonagenarians: Survey in a primary care hospital]
Bohlender J., Nussberger J., Ménard J., Bohlender B., 2017/06. Annales de cardiologie et d'angeiologie, 66 (3) pp. 130-134. Peer-reviewed.
 
Resetting of renal tissular renin-angiotensin and bradykinin-kallikrein systems after unilateral kidney denervation in rats.
Bohlender J.M., Nussberger J., Birkhäuser F., Grouzmann E., Thalmann G.N., Imboden H., 2017/05. Histochemistry and cell biology, 147 (5) pp. 585-593. Peer-reviewed.
 
Bradykinin in idiopathic non-histaminergic angioedema.
Cugno M., Tedeschi A., Nussberger J., 2017/01. Clinical and experimental allergy, 47 (1) pp. 139-140. Peer-reviewed.
 
Claire Douillard, Pascal Houillier, Juerg Nussberger and Xavier Girerd in response to the correspondence by Damien Denimal entitled: "Comments on French SFE/SFHTA/AFCE Consensus on Primary aldosteronism, Part 2: Diagnosis First steps". Ann Endocrinol 2016.
Douillard C., Houillier P., Nussberger J., Girerd X., 2016/12. Annales d'endocrinologie, 77 (6) p. 676. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_9E304BC94922]
 
Claire Douillard, Pascal Houillier, Juerg Nussberger and Xavier Girerd in response to the correspondence by Damien Denimal entitled: "Comments on French SFE/SFHTA/AFCE Consensus on Primary aldosteronism, Part 2: Diagnosis First steps". Ann Endocrinol 2016.
Douillard C., Houillier P., Nussberger J., Girerd X., 2016/12. Annales d'endocrinologie, 77 (6) p. 676. Peer-reviewed.
Unusual circadian hypertension associated with polydipsia.
Bohlender J.M., Nussberger J., 2016/11. Journal of geriatric cardiology : JGC, 13 (11) pp. 932-934. Peer-reviewed.
 
Antihypertensive treatment and risk of brain ischemia due to carotid stenosis in a survey of hospitalised patients aged 90 years and older
Bohlender Jürgen, Nussberger Jürg, Bohlender Beate, 2016/09., 26th Meeting of the International Society of Hypertension pp. e224 dans ISH 2016 Abstract Book, Journal of Hypertension.
 
SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps.
Douillard C., Houillier P., Nussberger J., Girerd X., 2016/07. Annales d'endocrinologie, 77 (3) pp. 192-201. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_38E4FBD8B60F]
 
SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.
Amar L., Baguet J.P., Bardet S., Chaffanjon P., Chamontin B., Douillard C., Durieux P., Girerd X., Gosse P., Hernigou A. et al., 2016/07. Annales d'endocrinologie, 77 (3) pp. 179-186. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_5E77715BCDCD]
 
Running Exercise and Angiotensin II Type I Receptor Blocker Telmisartan Are Equally Effective in Preventing Angiotensin II-Mediated Vulnerable Atherosclerotic Lesions.
Pellegrin M., Szostak J., Bouzourène K., Aubert J.F., Berthelot A., Nussberger J., Laurant P., Mazzolai L., 2016/04/30. Journal of cardiovascular pharmacology and therapeutics, 22 (2) pp. 159-168. Peer-reviewed.
 
CO-10: Are hospitalised patients aged 90 years and over treated well for hypertension? Lessons from a prospective survey.
Bohlender J., Nussberger J., Bohlender B., 2015. Annales de Cardiologie et d'angéiologie, 64 (Suppl 1) pp. S7. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_3FCC9C6F40C1]
 
Expression and functional role of the prorenin receptor in the human adrenocortical zona glomerulosa and in primary aldosteronism.
Recarti C., Seccia T.M., Caroccia B., Gonzales-Campos A., Ceolotto G., Lenzini L., Petrelli L., Belloni A.S., Rainey W.E., Nussberger J. et al., 2015. Journal of Hypertension, 33 (5) pp. 1014-1022. Peer-reviewed.
 
Le cophénotype sympathique efférent des fibres autonomes angiotensinergiques dans le coeur humain. [Autonomic angiotensinergic fibres in the human heart with an efferent sympathetic cophenotype]
Bohlender J., Nussberger J., Tevaearai H., Imboden H., 2015. Annales de Cardiologie et d'Angéiologie, 64 (3) pp. 175-179. Peer-reviewed.
Use of plasma Renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone.
Baumstark M.E., Nussberger J., Boretti F.S., Baumstark M.W., Riond B., Reusch C.E., Sieber-Ruckstuhl N.S., 2014. Journal of Veterinary Internal Medicine, 28 (5) pp. 1471-1478. Peer-reviewed.
 
Variabilité des concentrations plasmatiques de l'angiotensinogène et risque d'hypertension artérielle chez le rat transgénique [Variability of plasma angiotensinogen levels and risk of hypertension in a transgenic rat model].
Gudo B., Nussberger J., Bohlender J., 2014. Annales de Cardiologie et d'angéiologie, 63 (3) pp. 124-127. Peer-reviewed.
 
Angiotensinergic innervation of the kidney: present knowledge and its significance.
Bohlender J., Nussberger J., Imboden H., 2013. Current Hypertension Reports, 15 (1) pp. 10-16. Peer-reviewed.
 
Bradykinin in blood and cerebrospinal fluid after acute cerebral lesions: correlations with cerebral edema and intracranial pressure.
Kunz M., Nussberger J., Holtmannspötter M., Bitterling H., Plesnila N., Zausinger S., 2013. Journal of Neurotrauma, 30 (19) pp. 1638-1644.
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Schäfer N., Lohmann C., Winnik S., van Tits L.J., Miranda M.X., Vergopoulos A., Ruschitzka F., Nussberger J., Berger S., Lüscher T.F. et al., 2013. European Heart Journal, 34 (45) pp. 3515-3524.
 
Exercise-induced platelet activation in essential hypertension: have we solved the puzzle? Reply.
Kahan T., Schwieler J.H., Wallén H., Nussberger J., Hjemdahl P., 2013. Journal of Hypertension, 31 (9) p. 1917.
 
Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension.
Schwieler J.H., Kahan T., Wallén N.H., Nussberger J., Hjemdahl P., 2013. Journal of Hypertension, 31 (8) pp. 1676-1682.
 
La dénervation rénale unilatérale et le système kallikréine-bradykinine rénal chez le rat [Unilateral renal denervation and the renal kallikrein-bradykinin system in the rat].
Bohlender J., Nussberger J., Amstutz C., Birkhäuser F., Thalmann G.N., Imboden H., 2013. Annales de Cardiologie et d'angéiologie, 62 (3) pp. 144-148.
 
Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.
Nussberger J., Bohlender J., 2013. Nature Reviews. Cardiology, 10 (4) pp. 183-184.
 
Platelet activation during exercise is not attenuated by inhibition of the renin angiotensin system: the role of physical activity.
Kahan T., Schwieler J.H., Wallén H., Nussberger J., Hjemdahl P., 2013. Journal of Hypertension, 31 (10) pp. 2103-2104.
 
Reply: Optimal renin-angiotensin-aldosterone system blockade--wish fulfilled.
Nussberger J., Bohlender J., 2013. Nature Reviews. Cardiology, 10 (8) p. 486.
 
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
Boschmann M., Nussberger J., Engeli S., Danser A.H., Yeh C.M., Prescott M.F., Dahlke M., Jordan J., 2012. Journal of Hypertension, 30 (3) pp. 561-566.
 
Angiotensinergic innervation of the kidney: Localization and relationship with catecholaminergic postganglionic and sensory nerve fibers.
Bohlender J., Pfarrer B., Patil J., Nussberger J., Thalmann G.N., Imboden H., 2012. Histology and Histopathology, 27 (11) pp. 1413-1428.
 
Blood pressure and renin-angiotensin system resetting in transgenic rats with elevated plasma Val5-angiotensinogen.
Bohlender J., Bader M., Ménard J., Nussberger J., 2012. Journal of Hypertension, 30 (8) pp. 1597-1605.
 
Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study.
de Boer R.A., Azizi M., Danser A.J., Nguyen G., Nussberger J., Ruilope L.M., Schmieder R.E., Volpe M., 2012. Journal of the Renin-Angiotensin-Aldosterone System, 13 (3) pp. 409-412.
 
Intravital microscopy reveals endothelial dysfunction in resistance arterioles in Angiotensin II-induced hypertension.
Schäfer S.C., Pellegrin M., Wyss C., Aubert J.F., Nussberger J., Hayoz D., Lehr H.A., Mazzolai L., 2012. Hypertension Research, 35 (8) pp. 855-861.
 
Potassium restores vasorelaxation of resistance arterioles in non-hypertensive DOCA/salt fed mice.
Wyss C., Wang Q., Golshayan D., Nussberger J., Burnier M., Lehr H.A., Schaefer S.C., 2012. Microvascular Research, 84 (3) pp. 340-344.
 
Primärer Hyperaldosteronismus bei Katzen [Primary hyperaldosteronism in cats].
Willi B., Kook P.H., Quante S., Boretti F., Sieber-Ruckstuhl N.S., Grest P., Scherrer O., Riond B., Hofmann-Lehmann R., Nussberger J. et al., 2012. Schweizer Archiv für Tierheilkunde, 154 (12) pp. 529-537.
 
Vasopressin V(1a) receptors mediate posthemorrhagic systemic hypertension thereby determining rebleeding rate and outcome after experimental subarachnoid hemorrhage.
Hockel K., Schöller K., Trabold R., Nussberger J., Plesnila N., 2012. Stroke, 43 (1) pp. 227-232.
 
Aliskiren penetrates adipose and skeletal muscle tissue, and reduces Renin-Angiotensin System activity in obese hypertensive patients
Engeli S., Boschmann M., Nussberger J., Danser A. H. J., Yeh C. -M., Prescott M. F., Dahlke M., Jordan J., 2011. pp. 7-8 dans 77th Annual Meeting on German-Society-for-Experimental-and-Clinical-Pharmacology-and-Toxicology, Naunyn-Schmiedebergs Archives of Pharmacology. Peer-reviewed.
 
Angiotensinergic and noradrenergic neurons in the rat and human heart.
Patil J., Stucki S., Nussberger J., Schaffner T., Gygax S., Bohlender J., Imboden H., 2011. Regulatory Peptides, 167 (1) pp. 31-41.
Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
Hollenberg N.K., Fisher N.D., Nussberger J., Moukarbel G.V., Barkoudah E., Danser A.H., 2011. Journal of Hypertension, 29 (12) pp. 2454-2461.
 
Response to Letter Regarding Article, "Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease"
Sudano I., Flammer A.J., Periat D., Enseleit F., Hermann M., Wolfrum M., Hirt A., Kaiser P., Hurlimann D., Holzmeister J. et al., 2011. Circulation, 123 (25) pp. E646-E646.
 
The Renin prosequence enhances constitutive secretion of Renin and optimizes Renin activity.
Brakch N., Allemandou F., Keller I., Nussberger J., 2011. Current Neurovascular Research, 8 (2) pp. 121-130.
 
A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin.
Morganti A., European study group for the validation of DiaSorin LIAISON Direct Renin Assay, 2010. Journal of Hypertension, 28 (6) pp. 1307-1312.
 
Acetaminophen increases blood pressure in patients with coronary artery disease.
Sudano I., Flammer A.J., Périat D., Enseleit F., Hermann M., Wolfrum M., Hirt A., Kaiser P., Hurlimann D., Neidhart M. et al., 2010. Circulation, 122 (18) pp. 1789-1796.
 
Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.
Stanton Alice V., Gradman Alan H., Schmieder Roland E., Nussberger Juerg, Sarangapani Ramesh, Prescott Margaret F., 2010. Hypertension, 55 (1) pp. 54-60.
 
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals.
Zanchi A., Maillard M., Jornayvaz F.R., Vinciguerra M., Deleaval P., Nussberger J., Burnier M., Pechere-Bertschi A., 2010. Diabetologia, 53 (8) pp. 1568-1575.
Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.
Patil Jaspal, Schwab Alexander, Nussberger Juerg, Schaffner Thomas, Saavedra Juan M., Imboden Hans, 2010. Regulatory Peptides, 162 (1-3) pp. 90-98. Peer-reviewed.
 
The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.
Trabold Raimund, Eroes Christian, Zweckberger Klaus, Relton Jane, Beck Heike, Nussberger Juerg, Mueller-Esterl Werner, Bader Michael, Whalley Eric, Plesnila Nikolaus, 2010. Journal of Cerebral Blood Flow and Metabolism, 30 (1) pp. 130-139.
 
Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement.
Campbell D.J., Nussberger J., Stowasser M., Danser A.H., Morganti A., Frandsen E., Ménard J., 2009. Clinical Chemistry, 55 (5) pp. 867-877.
 
Angiotensin II is an endogenous neurotransmitter for rat and human mesenteric resistance blood vessels
Patil J., Heiniger E.v.a., Nussberger J., Schaffner T., Muehlemann O., Imboden H., 2009. pp. 34-34 dans Joint Meeting of the Society for Microcirculation and Vascular Biology Swiss Society for Microcirculation, Journal of Vascular Research. Peer-reviewed.
Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia.
Imboden H., Patil J., Nussberger J., Nicoud F., Hess B., Ahmed N., Schaffner T., Wellner M., Müller D., Inagami T. et al., 2009. Regulatory Peptides, 154 (1-3) pp. 23-31. Peer-reviewed.
Implication of chromosome 13 on hypertension and associated disorders in Lyon hypertensive rats.
Gilibert S., Bataillard A., Nussberger J., Sassard J., Kwitek A.E., 2009. Journal of Hypertension, 27 (6) pp. 1186-1193. Peer-reviewed.
 
Mesurer sa tension artérielle - il faut y penser! : campagne nationale sur la tension artérielle de la Fondation Suisse de Cardiologie
Mattle Heinrich, Nussberger Jürg, 2009. Swiss Medical Forum = Forum Médical Suisse, 21-22 p. 391.
 
Reninhemmer - Eine neue Klasse von Antihypertensiva
Nussberger Jürg, 2009., Uni-Med.
 
Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes.
Pellegrin M., Alonso F., Aubert J.F., Bouzourene K., Braunersreuther V., Mach F., Haefliger J.A., Hayoz D., Berthelot A., Nussberger J. et al., 2009. Hypertension, 53 (5) pp. 782-789.
 
Tension artérielle et infarcissement cérébral
Kappeler Liliane, Nussberger Jürg, Mattle Heinrich P., 2009. Swiss Medical Forum = Forum Médical Suisse, 21-22 pp. 392-397.
 
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.
Flammer A.J., Sudano I., Hermann F., Gay S., Forster A., Neidhart M., Künzler P., Enseleit F., Périat D., Hermann M. et al., 2008. Circulation, 117 (17) pp. 2262-2269.
 
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., Volk H.D., Stocker H., Müller P., Jennings G.T. et al., 2008. Lancet, 371 (9615) pp. 821-827.
 
Impfung gegen Angiotensin II--pro [Immunization against angiotensin II--pro]
Nussberger J., 2008. Deutsche Medizinische Wochenschrift, 133 (24) p. 1306. Peer-reviewed.
 
Low adiponectin is associated with increased ambulatory pulse pressure and activation of the renin-angiotensin system in subjects of African descent
Reyna-Carmona Laura-Elena, Bochud Murielle, Maillard Marc P., Bovet Pascal, Nussberger Jürg, Burnier Michel, Teta Daniel, 2008. pp. 10S dans 40th Annual Meeting Swiss Society of Nephrology, St. Gallen, December 3-5, 2008, Swiss Medical Weekly. Peer-reviewed.
 
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher N.D., Jan Danser A.H., Nussberger J., Dole W.P., Hollenberg N.K., 2008. Circulation, 117 (25) pp. 3199-3205.
 
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Nussberger J., Aubert J.F., Bouzourene K., Pellegrin M., Hayoz D., Mazzolai L., 2008. Hypertension, 51 (5) pp. 1306-1311.
 
The renin rise with aliskiren: it's simply stoichiometry.
Danser A.H., Charney A., Feldman D.L., Nussberger J., Fisher N., Hollenberg N., 2008. Hypertension, 51 (4) pp. e27-8; author reply e29.
 
Thiazide diuretic monotherapy for hypertension: diuretic's dark side just got darker.
Messerli F.H., Nussberger J., 2008. Kidney International, 74 (6) pp. 825; author reply 825.
 
Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension
Nussberger J., Gradman A. H., Schmieder R. E., Lins R. L., Chiang Y., Prescott M. F., 2007/09. International Journal of Clinical Practice, 61 (9) pp. 1461-8.
 
Effects of the Bradykinin B2 Receptor Antagonist Icatibant on Microvascular Permeability after Thermal Injury in Sheep
Jonkam C. C., Enkhbaatar P., Nakano Y., Boehm T., Wang J., Nussberger J., Esechie A., Traber L. D., Herndon D., Traber D. L., 2007/06. Shock.
 
Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)
Bork K., Frank J., Grundt B., Schlattmann P., Nussberger J., Kreuz W., 2007/06. Journal of Allergy and Clinical Immunology, 119 (6) pp. 1497-503.
 
Blutdrucksenkende Tripeptide aus der Milch [Blood pressure lowering tripeptides derived from milk protein]
Nussberger J., 2007/03. Therapeutische Umschau, 64 (3) pp. 177-179.
 
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker
O'Brien E., Barton J., Nussberger J., Mulcahy D., Jensen C., Dicker P., Stanton A., 2007/02. Hypertension, 49 (2) pp. 276-84.
 
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., Nief V., Schellekens C., Sladko K., Roubicek K. et al., 2007/01. Journal of Hypertension, 25 (1) pp. 63-72.
 
CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt.
Eap C.B., Bochud M., Elston R.C., Bovet P., Maillard M.P., Nussberger J., Schild L., Shamlaye C., Burnier M., 2007. Hypertension, 49 (5) pp. 1007-14. Peer-reviewed.
 
Expression and secretion of the atrial natriuretic peptide in human adipose tissue and preadipocytes.
Garruti G., Giusti V., Nussberger J., Darimont C., Verdumo C., Amstutz C., Puglisi F., Giorgino F., Giorgino R., Cotecchia S., 2007. Obesity, 15 (9) pp. 2181-2189. Peer-reviewed.
 
Reply to 'Blood pressure vaccine shot down by safety concerns'
Bachmann M. F., Nussberger J., Tissot A. C., Jennings G. T., 2006/03. Natural Medicines, 12 (3) p. 270.
 
Renin inhibition with aliskiren: where are we now, and where are we going?
Azizi M., Webb R., Nussberger J., Hollenberg N. K., 2006/02. Journal of Hypertension, 24 (2) pp. 243-56.
 
Plasma aldosterone is independently associated with the metabolic syndrome.
Bochud M., Nussberger J., Bovet P., Maillard M.R., Elston R.C., Paccaud F., Shamlaye C., Burnier M., 2006. Hypertension, 48 (2) pp. 239-45. Peer-reviewed.
 
Severe hyperlipidemia causes impaired renin-angiotensin system function in apolipoprotein E deficient mice.
Mazzolai L., Korber M., Bouzourene K., Aubert J.F., Nussberger J., Stamenkovic I., Hayoz D., 2006. Atherosclerosis, 186 (1) pp. 86-91. Peer-reviewed.
 
The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
Zanchi A., Perregaux C., Maillard M., Cefai D., Nussberger J., Burnier M., 2006. American journal of physiology. Endocrinology and metabolism, 291 (6) pp. E1228-34. Peer-reviewed.
 
Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice
Groger M., Lebesgue D., Pruneau D., Relton J., Kim S. W., Nussberger J., Plesnila N., 2005/08. Journal of Cerebral Blood Flow and Metabolism, 25 (8) pp. 978-89.
 
Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation
Cugno M., Agostoni P., Mari D., Meroni P. L., Gregorini L., Bussotti M., Anguissola G. B., Donatelli F., Nussberger J., 2005/07. British Journal of Haematology, 130 (1) pp. 113-20.
 
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage
Fiebeler A., Nussberger J., Shagdarsuren E., Rong S., Hilfenhaus G., Al-Saadi N., Dechend R., Wellner M., Meiners S., Maser-Gluth C. et al., 2005/06. Circulation, 111 (23) pp. 3087-94.
 
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
Gradman A. H., Schmieder R. E., Lins R. L., Nussberger J., Chiang Y., Bedigian M. P., 2005/03. Circulation, 111 (8) pp. 1012-8.
 
Metoprolol prevents sodium retention induced by lower body negative pressure in healthy men.
Wuerzner G., Chiolero A., Maillard M., Nussberger J., Burnier M., 2005. Kidney International, 68 (2) pp. 688-694. Peer-reviewed.
 
Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C., Nussberger J., Maillard M., Forclaz A., Brunner H.R., Burnier M., 2005. Clinical pharmacology and therapeutics, 78 (5) pp. 501-7. Peer-reviewed.
 
The renin-angiotensin-aldosterone-system
Mazzolai L., Nussberger J., 2005. pp. 143-156 dans Battegay E., Lip G., Bakris G. (eds.) Hypertension : principles and practice chap. 9, Taylor & Francis.
 
Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism
Ferrari P., Shaw S. G., Nicod J., Saner E., Nussberger J., 2004/02. Journal of Hypertension, 22 (2) pp. 377-81.
 
Angiotensin II receptor blockade prevents acute renal sodium retention induced by low levels of orthostatic stress.
Wuerzner G., Chioléro A., Maillard M., Nussberger J., Brunner H.R., Burnier M., Chiclero A., 2004. Kidney International, 65 (1) pp. 238-244. Peer-reviewed.
 
Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil
Nussberger J., Koike H., 2004. Clinical Therapeutics, 26 Suppl A pp. A12-20.
 
Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.
Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2004. Journal of Clinical Endocrinology and Metabolism, 89 (3) pp. 1140-1145. Peer-reviewed.
 
Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice.
Mazzolai L., Duchosal M.A., Korber M., Bouzourene K., Aubert J.F., Hao H., Vallet V., Brunner H.R., Nussberger J., Gabbiani G. et al., 2004. Hypertension, 44 (3) pp. 277-82.
 
Renal endothelin receptor type B upregulation in rats with low or high renin hypertension.
Brakch N., Abdel-Sayed S., Allemandou F., Wang Q., Aubert J.F., Brunner H.R., Nussberger J., 2004. Journal of hypertension, 22 (9) pp. 1797-803. Peer-reviewed.
 
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
Stanton A., Jensen C., Nussberger J., O'Brien E., 2003/12. Hypertension, 42 (6) pp. 1137-43.
 
Bradykinin and the pathophysiology of angioedema
Cugno M., Nussberger J., Cicardi M., Agostoni A., 2003/03. International Immunopharmacology, 3 (3) pp. 311-7.
 
Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?
Forclaz A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2003. Hypertension, 41 (1) pp. 31-6.
 
Blood pressure regulation in low renin subjects.
Brakch N., Nussberger J., 2003. Journal of hypertension, 21 (10) pp. 1821-2. Peer-reviewed.
 
Investigating mineralocorticoid hypertension.
Nussberger J., 2003. Journal of Hypertension. Supplement, 21 (2) pp. 25-30.
 
Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects.
Abdel-Sayed S., Nussberger J., Aubert J.F., Gohlke P., Brunner H.R., Brakch N., 2003. American journal of hypertension, 16 (7) pp. 515-21. Peer-reviewed.
Rapid Site-Directed Mutagenesis Using Two-PCR-Generated DNA Fragments Reproducing the Plasmid Template.
Allemandou F., Nussberger J., Brunner H.R., Brakch N., 2003. Journal of biomedicine & biotechnology, 2003 (3) pp. 202-207.
 
Volume expansion enhances plasma endothelin-1.
Abdel-Sayed S., Brunner H.R., Nussberger J., 2003. American journal of hypertension, 16 (12) pp. 1057-61. Peer-reviewed.
 
Bradykinin-mediated angioedema
Nussberger J., Cugno M., Cicardi M., 2002/08. New England Journal of Medicine, 347 (8) pp. 621-2.
 
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril
Nussberger J., Wuerzner G., Jensen C., Brunner H. R., 2002/01. Hypertension, 39 (1) pp. E1-8.
 
Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes.
Wang Q., Hummler E., Nussberger J., Clément S., Gabbiani G., Brunner H.R., Burnier M., 2002. Journal of the American Society of Nephrology, 13 (6) pp. 1509-1516. Peer-reviewed.
 
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard M.P., Würzner G., Nussberger J., Centeno C., Burnier M., Brunner H.R., 2002. Clinical pharmacology and therapeutics, 71 (1) pp. 68-76. Peer-reviewed.
 
Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2002. Hypertension, 40 (3) pp. 266-72.
 
Bradykinin in the ascitic fluid of patients with liver cirrhosis.
Cugno M., Salerno F., Nussberger J., Bottasso B., Lorenzano E., Agostoni A., 2001/12. Clinical Science, 101 (6) pp. 651-657. Peer-reviewed.
 
Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion
Cugno M., Nussberger J., Biglioli P., Alamanni F., Coppola R., Agostoni A., 2001/12. Chest, 120 (6) pp. 1776-82.
 
Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist
Brunner H. R., Nussberger J., 2001/06. Journal of Hypertension. Supplement, 19 (1) pp. S15-20.
 
Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice
Meneton P., Bloch-Faure M., Hagege A. A., Ruetten H., Huang W., Bergaya S., Ceiler D., Gehring D., Martins I., Salmon G. et al., 2001/02. Proceedings of the National Academy of Sciences of the United States of America, 98 (5) pp. 2634-9.
 
Circulating versus tissue angiotensin II
Nussberger J., 2001. pp. 69-78 dans Epstein Murray (eds.) Angiotensin II receptor antagonists, Hanley & Belfus.
 
Compensatory up-regulation of angiotensin II subtype 1 receptors in alpha ENaC knockout heterozygous mice.
Wang Q., Hummler E., Maillard M., Nussberger J., Rossier B.C., Brunner H.R., Burnier M., 2001. Kidney international, 59 (6) pp. 2216-21. Peer-reviewed.
 
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2.
Pellieux C., Foletti A., Peduto G., Aubert J.F., Nussberger J., Beermann F., Brunner H.R., Pedrazzini T., 2001. Journal of Clinical Investigation, 108 (12) pp. 1843-1851. Peer-reviewed.
 
Measurement of immunoreactive angiotensin-(1-7) heptapeptide in human blood.
Nussberger J., Brunner D.B., Nyfeler J.A., Linder L., Brunner H.R., 2001. Clinical chemistry, 47 (4) pp. 726-9. Peer-reviewed.
 
Renal and neurohormonal responses to increasing levels of lower body negative pressure in men.
Würzner G., Chiolero A., Maillard M., Nussberger J., Hayoz D., Brunner H.R., Burnier M., 2001. Kidney international, 60 (4) pp. 1469-76. Peer-reviewed.
 
Plasma bradykinin levels in human chronic congestive heart failure.
Cugno M., Agostoni P., Brunner H.R., Gardinali M., Agostoni A., Nussberger J., 2000/11. Clinical Science, 99 (5) pp. 461-466. Peer-reviewed.
 
Vasopeptidase inhibition and angio-oedema
Messerli F. H., Nussberger J., 2000/08. Lancet, 356 (9230) pp. 608-9.
 
Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability
Schieffer B., Schieffer E., Hilfiker-Kleiner D., Hilfiker A., Kovanen P. T., Kaartinen M., Nussberger J., Harringer W., Drexler H., 2000/03. Circulation, 101 (12) pp. 1372-8.
 
Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Brunner-Ferber F., Brunner H.R., Biollaz J., 2000. European journal of clinical pharmacology, 55 (10) pp. 749-54. Peer-reviewed.
 
Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice.
Mazzolai L., Pedrazzini T., Nicoud F., Gabbiani G., Brunner H.R., Nussberger J., 2000. Hypertension, 35 (4) pp. 985-91. Peer-reviewed.
 
Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.
Maillard M.P., Rossat J., Nussberger J., Ramis J., Pontes C., Burnier M., Brunner H.R., 2000. Journal of cardiovascular pharmacology, 35 (3) pp. 383-9. Peer-reviewed.
 
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt.
Chiolero A., Maillard M., Nussberger J., Brunner H.R., Burnier M., 2000. Hypertension, 36 (4) pp. 631-7.
 
Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading.
Burnier M., Monod M.L., Chioléro A., Maillard M., Nussberger J., Brunner H.R., 2000. Journal of hypertension, 18 (11) pp. 1657-64. Peer-reviewed.
 
Local bradykinin generation in hereditary angioedema
Nussberger J., Cugno M., Cicardi M., Agostoni A., 1999/12. Journal of Allergy and Clinical Immunology, 104 (6) pp. 1321-2.
 
Angioedema due to angiotensin-converting enzyme inhibitors
Agostoni A., Cicardi M., Cugno M., Zingale L. C., Gioffre D., Nussberger J., 1999/10. Immunopharmacology, 44 (1-2) pp. 21-5.
 
Cardiopulmonary bypass increases plasma bradykinin concentrations
Cugno M., Nussberger J., Biglioli P., Giovagnoni M. G., Gardinali M., Agostoni A., 1999/09. Immunopharmacology, 43 (2-3) pp. 145-7.
 
Coadministration of albumin and furosemide in patients with the nephrotic syndrome
Fliser D., Zurbruggen I., Mutschler E., Bischoff I., Nussberger J., Franek E., Ritz E., 1999/02. Kidney International, 55 (2) pp. 629-34.
 
[Does constitutional hypotension exist?]
Pechere-Bertschi A., Nussberger J., Burnier M., 1999/01. Therapeutische Umschau, 56 (1) pp. 49-54.
 
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L., Maillard M., Rossat J., Nussberger J., Brunner H.R., Burnier M., 1999. Hypertension, 33 (3) pp. 850-5. Peer-reviewed.
 
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Maillard M.P., Mazzolai L., Daven V., Centeno C., Nussberger J., Brunner H.R., Burnier M., 1999. American journal of hypertension, 12 (12 Pt 1-2) pp. 1201-8. Peer-reviewed.
 
Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats.
Haefliger J.A., Waeber B., Grouzmann E., Braissant O., Nussberger J., Nicod P., Waeber G., 1999. Regulatory peptides, 82 (1-3) pp. 35-43. Peer-reviewed.
 
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Décosterd L.A., La Roche S.D., Brunner-Ferber F., Brunner H.R., Biollaz J., 1999. Journal of Hypertension, 17 (3) pp. 427-437. Peer-reviewed.
 
Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects.
Burnier M., Fricker A.F., Hayoz D., Nussberger J., Brunner H.R., 1999. European journal of clinical pharmacology, 55 (9) pp. 633-7. Peer-reviewed.
 
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
Rossat J., Maillard M., Nussberger J., Brunner H.R., Burnier M., 1999. Clinical pharmacology and therapeutics, 66 (1) pp. 76-84. Peer-reviewed.
 
Plasma bradykinin in angio-oedema
Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A., 1998/06. Lancet, 351 (9117) pp. 1693-7.
 
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system.
Mazzolai L., Nussberger J., Aubert J.F., Brunner D.B., Gabbiani G., Brunner H.R., Pedrazzini T., 1998. Hypertension, 31 (6) pp. 1324-30. Peer-reviewed.
 
Circadian variations of renal sodium handling in patients with orthostatic hypotension.
Pechère-Bertschi A., Nussberger J., Biollaz J., Fahti M., Grouzmann E., Morgan T., Brunner H.R., Burnier M., 1998. Kidney international, 54 (4) pp. 1276-82. Peer-reviewed.
 
Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects.
Fricker A.F., Nussberger J., Meilenbrock S., Brunner H.R., Burnier M., 1998. Kidney international, 54 (6) pp. 2089-97. Peer-reviewed.
 
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Brunner-Ferber F., Brunner H.R., Biollaz J., 1998. Journal of Cardiovascular Pharmacology, 31 (3) pp. 408-417. Peer-reviewed.
 
Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A., Nussberger J., Decosterd L., Armagnac C., Sissmann J., Bouroudian M., Brunner H.R., Burnier M., 1998. Journal of hypertension, 16 (3) pp. 385-93. Peer-reviewed.
 
Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients
Puchler K., Nussberger J., Laeis P., Witte P. U., Brunner H. R., 1997/12. Journal of Hypertension, 15 (12 Pt 2) pp. 1809-12.
 
SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers
Hagmann M., Nussberger J., Naudin R. B., Burns T. S., Karim A., Waeber B., Brunner H. R., 1997/04. Journal of Cardiovascular Pharmacology, 29 (4) pp. 444-50.
 
Plasma angiotensins and human forearm circulation: effects of sympatho-adrenal activation
Kahan T., Lindqvist M., Nussberger J., Melcher A., Hjemdahi P., 1997/02. Acta Physiologica Scandinavica, 159 (2) pp. 107-11.
 
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
Goldberg M.R., Lo M.W., Christ D.D., Chiou R., Furtek C.I., Amit O., Carides A., Biollaz J., Piguet V., Nussberger J. et al., 1997. Clinical pharmacology and therapeutics, 61 (1) pp. 59-69. Peer-reviewed.
 
Two-kidney, one clip and one-kidney, one clip hypertension in mice.
Wiesel P., Mazzolai L., Nussberger J., Pedrazzini T., 1997. Hypertension, 29 (4) pp. 1025-30. Peer-reviewed.
 
Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081.
Noël B., Del Re G., Capone P., Brunner H.R., Nussberger J., 1996. Journal of Cardiovascular Pharmacology, 28 (2) pp. 252-258. Peer-reviewed.
 
Effects of neuropeptide Y on intrarenal hemodynamics, plasma renin activity and urinary sodium excretion in rats.
Evéquoz D., Aubert J.F., Nussberger J., Biollaz J., Diezi J., Brunner H.R., Waeber B., 1996. Nephron, 73 (3) pp. 467-72. Peer-reviewed.
 
Experience with angiotensin II antagonists in hypertensive patients.
Waeber B., Burnier M., Nussberger J., Brunner H.R., 1996. Clinical and experimental pharmacology & physiology. Supplement, 3 pp. S142-6.
 
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier M., Buclin T., Biollaz J., Nussberger J., Waeber B., Brunner H.R., 1996. Kidney international. Supplement, 55 pp. S24-9.
 
Principles and practice of angiotensin-converting enzyme inhibitors
Brunner H. R., Waeber B., Nussberger J., 1996. pp. 690-711 dans Messerli F.H. (eds.) Cardiovascular Drug Therapy, WB Saunders.
 
Volemic status influences the response of plasma atrial natriuretic factor to positive airway pressure.
Beuret P., Feihl F., Nussberger J., Brunner H.R., Perret C., 1996. Chest, 109 (5) pp. 1313-9. Peer-reviewed.
 
Beneficial clinical effect of very early enalapril treatment in patients with acute left ventricular failure complicating myocardial infarction
Huttl S., Nussberger J., Lehmann K., Hasford J., Brunner H. R., Delius W., 1995/06. Clinical Cardiology, 18 (6) pp. 317-23.
 
Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I
Inglessis N., Nussberger J., Hagmann M., Hiesse-Provost O., Insuasty J., Reid J., Menard J., Brunner H. R., 1995/06. Journal of Cardiovascular Pharmacology, 25 (6) pp. 986-93.
 
Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system.
Zanchi A., Schaad N.C., Osterheld M.C., Grouzmann E., Nussberger J., Brunner H.R., Waeber B., 1995/06. American Journal of Physiology. Heart and Circulatory Physiology, 268 (6 Pt 2) pp. H2267-H2273.
 
Beta-adrenoceptor stimulation increases neuropeptide Y release from sympathetic nerves in intact rats.
Evéquoz D., Grouzmann E., Nussberger J., Niederberger M., Brunner H.R., Waeber B., 1995. Regulatory peptides, 58 (3) pp. 163-6. Peer-reviewed.
 
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
Delacrétaz E., Nussberger J., Biollaz J., Waeber B., Brunner H.R., 1995. Hypertension, 25 (1) pp. 14-21. Peer-reviewed.
 
Chronic nitric oxide synthase inhibition and carotid artery distensibility in renal hypertensive rats.
Delacrétaz E., Zanchi A., Nussberger J., Hayoz D., Aubert J.F., Brunner H.R., Waeber B., 1995. Hypertension, 26 (2) pp. 332-6. Peer-reviewed.
 
Effect of epinephrine on oxygen consumption and delivery during progressive hemorrhage.
Revelly J.P., Gardaz J.P., Nussberger J., Schutz Y., Chioléro R., 1995. Critical Care Medicine, 23 (7) pp. 1272-1278. Peer-reviewed.
 
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Favrat B., Burnier M., Nussberger J., Lecomte J.M., Brouard R., Waeber B., Brunner H.R., 1995. Journal of hypertension, 13 (7) pp. 797-804. Peer-reviewed.
 
Renin and angiotensin II receptor gene expression in kidneys of renal hypertensive rats.
Haefliger J.A., Bergonzelli G., Waeber G., Aubert J.F., Nussberger J., Gavras H., Nicod P., Waeber B., 1995. Hypertension, 26 (5) pp. 733-7. Peer-reviewed.
 
Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
Burnier M., Hagman M., Nussberger J., Biollaz J., Armagnac C., Brouard R., Weber B., Brunner H.R., 1995. Hypertension, 25 (4 Pt 1) pp. 602-609. Peer-reviewed.
 
Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
Burnier M., Pechère-Bertschi A., Nussberger J., Waeber B., Brunner H.R., 1995. American Journal of Kidney Diseases, 26 (1) pp. 108-115. Peer-reviewed.
 
Sympathetic nerve activity in conscious renal hypertensive rats treated with an angiotensin converting enzyme inhibitor or an angiotensin II antagonist.
Niederberger M., Aubert J.F., Nussberger J., Brunner H.R., Waeber B., 1995. Journal of Hypertension, 13 (4) pp. 439-445. Peer-reviewed.
 
Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Dusseldorf, Munich, Germany
Nussberger J., Fleck E., Bahrmann H., Delius W., Schultheiss H. P., Brunner H. R., 1994/12. European Heart Journal, 15 Suppl D pp. 113-22.
 
Dose-response relationships of ACE inhibitors and angiotensin II blockers
Brunner H. R., Nussberger J., Waeber B., 1994/12. European Heart Journal, 15 Suppl D pp. 123-8.
 
Individual measurements of angiotensin II concentrations in aqueous humor of the eye
Osusky R., Nussberger J., Amstutz C., Flammer J., Brunner H. R., 1994/12. European Journal of Ophthalmology, 4 (4) pp. 228-33.
 
Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects.
Pellacani A., Brunner H.R., Nussberger J., 1994/11. Clinical Science, 87 (5) pp. 567-574. Peer-reviewed.
 
Reciprocal changes in vasoactive hormones in the rat myocardial infarction model of heart failure.
Zelis R., Nussberger J., Niederberger M., Zelis G.A., Genton C., Waeber B., Brunner H.R., 1994/10. Journal of cardiac failure, 1 (1) pp. 63-69. Peer-reviewed.
 
Participation of prostaglandins and bradykinin in the effects of angiotensin II and converting enzyme-inhibition on sympathetic neurotransmission in vivo
Schwieler J. H., Kahan T., Nussberger J., Hjemdahl P., 1994/09. Acta Physiologica Scandinavica, 152 (1) pp. 83-91.
 
Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition
Delacretaz E., Nussberger J., Puchler K., Wood A. J., Robinson P. R., Waeber B., Brunner H. R., 1994/09. Journal of Cardiovascular Pharmacology, 24 (3) pp. 479-85.
 
Angiotensin II overflow from canine skeletal muscle in vivo: importance of plasma angiotensin I
Schwieler J. H., Nussberger J., Kahan T., Hjemdahl P., 1994/05. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 266 (5 Pt 2) pp. R1664-9.
 
R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers
Zusman R. M., Hui K. Y., Nussberger J., Christensen D. M., Higgins J., Carlson W. D., Schoenfeld D., Haber E., 1994/04. American Journal of Hypertension, 7 (4 Pt 1) pp. 295-301.
 
Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm
Clemson B., Gaul L., Gubin S. S., Campsey D. M., McConville J., Nussberger J., Zelis R., 1994/02. Journal of Clinical Investigation, 93 (2) pp. 684-91.
 
Angiotensin II antagonists DuP 753 and TCV 116.
Brunner H.R., Delacrétaz E., Nussberger J., Burnier M., Waeber B., 1994. Journal of Hypertension. Supplement, 12 (9) pp. S29-34.
 
Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.
Zanchi A., Nussberger J., Criscuoli M., Capone P., Brunner H.R., 1994. Journal of cardiovascular pharmacology, 24 (2) pp. 317-22. Peer-reviewed.
 
Mechanisms of the pressor response to intravenous thyrotropin-releasing hormone in the rat.
Evequoz D., Burnier M., Niederberger M., Brunner H.R., Nussberger J., Waeber B., 1994. Clinical and experimental pharmacology & physiology, 21 (2) pp. 93-100. Peer-reviewed.
 
Neuropeptide Y infusion decreases plasma renin activity in postmyocardial infarction rats.
Zelis R., Nussberger J., Clemson B., Waeber B., Grouzmann E., Brunner H.R., 1994. Journal of cardiovascular pharmacology, 24 (6) pp. 896-9. Peer-reviewed.
 
Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment
Neubeck M., Fliser D., Pritsch M., Weisser K., Fliser M., Nussberger J., Ritz E., Mutschler E., 1994. European Journal of Clinical Pharmacology, 46 (6) pp. 537-43.
 
Control of vascular tone by renin and angiotensin in cardiovascular disease
Brunner H. R., Nussberger J., Waeber B., 1993/11. European Heart Journal, 14 Suppl I pp. 149-53.
 
Hygroma renale: pararenal lymphatic cysts associated with renin-dependent hypertension (Page kidney). Case report on bilateral cysts and successful therapy by marsupialization
Schwarz A., Lenz T., Klaen R., Offermann G., Fiedler U., Nussberger J., 1993/09. Journal of Urology, 150 (3) pp. 953-7.
 
Aging and human hormonal and pressor responsiveness to angiotensin II infusion with simultaneous measurement of exogenous and endogenous angiotensin II
Duggan J., Nussberger J., Kilfeather S., O'Malley K., 1993/08. American Journal of Hypertension, 6 (8) pp. 641-7.
 
Effect of monoclonal anti-ANP antibodies on the acute functional adaptation to unilateral nephrectomy
Valentin J. P., Ribstein J., Neuser D., Nussberger J., Mimran A., 1993/06. Kidney International, 43 (6) pp. 1260-6.
 
Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system
Brunner H. R., Nussberger J., Waeber B., 1993/04. Journal of Hypertension. Supplement, 11 (3) pp. S53-8.
 
Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms
Schwieler J. H., Kahan T., Nussberger J., Hjemdahl P., 1993/04. American Journal of Physiology. Endocrinology and Metabolism, 264 (4 Pt 1) pp. E631-7.
 
[Blood pressure recording in outpatient service: experience with the Sandoz Pressure System]
Porchet M., Nussberger J., Brunner H. R., Waeber B., 1993/03. Schweizerische Rundschau fur Medizin Praxis, 82 (11) pp. 320-2.
 
Inhibitors of the renin-angiotensin system
Brunner H. R., Nussberger J., Waeber B., 1993/02. Arzneimittel-Forschung, 43 (2A) pp. 274-8.
 
Angiotensin antagonists
Brunner H. R., Nussberger J., Waeber B., 1993. Advances in Nephrology from the Necker Hospital, 22 pp. 305-27.
 
Angiotensin II antagonists.
Brunner H.R., Nussberger J., Burnier M., Waeber B., 1993. Clinical and experimental hypertension, 15 (6) pp. 1221-38. Peer-reviewed.
 
Natriuretic and vasoactive hormones and glomerular hyperfiltration in hyperglycaemic type 2 diabetic patients: effect of insulin treatment
Lalau J. D., Westeel P. F., Tenenbaum F., Debussche X., Nussberger J., Tribout B., Fardelonne P., Favre H., Fournier A., 1993. Nephron, 63 (3) pp. 296-302.
 
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
Burnier M., Rutschmann B., Nussberger J., Versaggi J., Shahinfar S., Waeber B., Brunner H.R., 1993. Hypertension, 22 (3) pp. 339-47. Peer-reviewed.
 
The renin-angiotensin system and arterial wall behavior.
Hayoz D., Nussberger J., Waeber B., Brunner H.R., 1993. Journal of cardiovascular pharmacology, 22 Suppl 5 pp. S48-52. Peer-reviewed.
 
[What have we learned from converting enzyme inhibitors on renin-angiotensin system?]
Waeber B., Nussberger J., Brunner H. R., 1992/12. Revue du Praticien, 42 (20) pp. 2529-32.
 
Clinical experience with angiotensin II receptor antagonists
Brunner H. R., Christen Y., Munafo A., Lee R. J., Waeber B., Nussberger J., 1992/12. American Journal of Hypertension, 5 (12 Pt 2) pp. 243S-246S.
 
Strategies for the management of hypertension in aircrew
Brunner H. R., Waeber B., Nussberger J., 1992/12. European Heart Journal, 13 Suppl H pp. 45-9.
 
[Renin-angiotensin system blockade. What can be expected from angiotensin II antagonists?]
Waeber B., Nussberger J., Brunner H., 1992/10. Revue du Praticien, 42 (16) pp. 2066-8.
 
Effects of aging and hypertension on plasma angiotensin II and platelet angiotensin II receptor density
Duggan J., Kilfeather S., O'Brien E., O'Malley K., Nussberger J., 1992/10. American Journal of Hypertension, 5 (10) pp. 687-93.
 
Influence of angiotensin II, alpha- and beta-adrenoceptors on peripheral noradrenergic neurotransmission in canine gracilis muscle in vivo
Schwieler J. H., Kahan T., Nussberger J., Johansson M. C., Hjemdahl P., 1992/08. Acta Physiologica Scandinavica, 145 (4) pp. 333-43.
 
Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II. Comparison with two other methods
Nussberger J., Brunner D., Keller I., Brunner H. R., 1992/06. American Journal of Hypertension, 5 (6 Pt 1) pp. 393-8.
 
Chronic adriamycin treatment and its effect on the cardiac beta-adrenergic system in the rabbit
Bocherens-Gadient S. A., Quast U., Nussberger J., Brunner H. R., Hof R. P., 1992/05. Journal of Cardiovascular Pharmacology, 19 (5) pp. 770-8.
 
[Preliminary evaluation of the Profilomat, a new portable blood pressure recorder]
Ganslmayer M., Perret F., Waeber B., Nussberger J., Brunner H. R., 1992/04. Schweizerische Medizinische Wochenschrift, 122 (15) pp. 544-8.
 
[Practical consequences blood pressure variability]
Waeber B., Niederberger M., Nussberger J., Brunner H. R., 1992/02. Schweizerische Rundschau fur Medizin Praxis, 81 (7) pp. 183-7.
 
Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure
Fitzpatrick M. A., Rademaker M. T., Charles C. J., Yandle T. G., Espiner E. A., Ikram H., Nussberger J., 1992/02. Journal of Cardiovascular Pharmacology, 19 (2) pp. 169-75.
 
Antagonizing and measurement: approaches to understanding of hemodynamic effects of kinins
Pellacani A., Brunner H. R., Nussberger J., 1992. Journal of Cardiovascular Pharmacology, 20 Suppl 9 pp. S28-34.
Arzneimittelbedingte Tosdesfälle
Biollaz J., Nussberger J., Schelling J.L., 1992. pp. 135-145 dans Berg P.S. (eds.) Unerwartete Todesfälle in Klinik und Praxis, Springer.
 
Conduit artery compliance and distensibility are not necessarily reduced in hypertension.
Hayoz D., Rutschmann B., Perret F., Niederberger M., Tardy Y., Mooser V., Nussberger J., Waeber B., Brunner H.R., 1992. Hypertension, 20 (1) pp. 1-6. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University